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Abstract Nicotinic acetylcholine receptors (nAChRs) containing α 6 and β 2 subunits modulate dopamine release in the basal ganglia and are therapeutically relevant targets for treatment of neurological and psychiatric disorders including Parkinson's disease and nicotine dependence. However, the expression profile of β 2 and β 4 subunits overlap in a variety of tissues including locus coeruleus, retina, hippocampus, dorsal root ganglia, and adrenal chromaffin cells. Ligands that bind α 6β2 nAChRs also potently bind the closely related α 6β4 subtype. To distinguish between these two subtypes, we synthesized novel analogs of a recently described α -conotoxin, PeIA. PeIA is a peptide antagonist that blocks several nAChR subtypes, including α 6/α3β2β3 and α 6/α3β4 nAChRs, with low nanomolar potency. We systematically mutated PeIA and evaluated the resulting analogs for enhanced potency and/or selectivity for α 6/α3β2β3 nAChRs expressed in . The synthesis of PeIA [S9H,V10A,E14N] demonstrates that ligands can be developed to discriminate between α 6β2 and α 6β4 nAChRs. MOL # 80853 Introduction Mammalian neuronal nicotinic acetylcholine receptors (nAChRs) assemble in a pentameric stoichimetry from eight α and three β subunits to form various receptor subtypes.
Selective ligands have played a critical role in identifying individual subtypes and defining their physiological functions. nAChR subtypes that contain the α 6 subunit have a very restricted tissue distribution. In the central nervous system (CNS), α 6-containing nAChRs are expressed in dopaminergic regions including the substantia nigra, ventral tegmental area, and the nucleus accumbens (Gotti et al., 2010; Yang et al., 2009) . Dopaminergic neurons of the substantia nigra are gradually lost in Parkinson's disease which leads to disordered control over motor movement (Bordia et al., 2007) . In reward centers of the brain, activation of α 6-containing nAChRs enhances dopamine release and reinforces the addictive properties of nicotine (Brunzell et al., 2010; Exley et al., 2011; Jackson et al., 2009; Liu et al., 2012; Pons et al., 2008) . In these midbrain areas, α 6 subunits assemble with β 2 subunits to form α 6β2* nAChRs (asterisk denotes the possible presence of additional subunits); areas where expression of the β 4 subunit is minimal or absent and therefore, few, if any, α 6β4* nAChRs are likely to be present. Thus, ligands that bind α 6* nAChRs can be used in these regions to selectively identify α 6β2* nAChRs. However, in other areas such as the retina (Marritt et al., 2005; Moretti et al., 2004) and the locus coeruleus (Azam and McIntosh, 2006; Lena et al., 1999; Vincler and Eisenach, 2003 ) α 6β4* nAChRs are present and may be co-expressed with the α 6β2* subtype. Moreover, in the hippocampus of mouse, α 6β4* nAChRs control the release of norepinephrine (Azam et al., 2010) . Lastly, in the peripheral nervous system, α 6β4* nAChRs are expressed by human adrenal chromaffin cells (Perez-Alvarez et al., 2012) and by rat dorsal root ganglion neurons (Hone et al., 2012) , two cell populations that also have substantial β 2 subunit expression. Thus, ligands MOL # 80853 5 that can discriminate between α 6β2* and α 6β4* nAChRs are needed to facilitate the study of α 6β2* nAChRs in areas where multiple α 6-containing nAChRs are potentially expressed.
Predatory cone snails (Conus) have evolved a rich, combinatorial-like library of neuropharmacologically active compounds. Among the principal components of the cone snail venom are the α -conotoxins (α-Ctxs), disulfide-rich peptide antagonists of nAChRs. Each species of cone snail produces several distinct α -Ctxs as part of its venom arsenal to immobilize prey. Subsets of these α -Ctxs are now widely employed by neuroscientists to block the function of mammalian nAChR subtypes (Armishaw, 2010; Azam and McIntosh, 2009) . However, as the diversity of nAChR subtypes is progressively elucidated, the need for increasingly selective ligands correspondingly grows. Several existing α -Ctxs potently block α 6 nAChRs. However, α -Ctxs that block α 6/α3β2β3 nAChRs also potently block α 6/α3β4 nAChRs (Dowell et al., 2003) .
Thus, further refinement of the specificity of these ligands is required.
α -Ctx PeIA, cloned from a cDNA library of Conus pergrandis, potently blocks several nAChRs subtypes including those that contain the α 6 subunit . We used α -Ctx PeIA as a template to create ligands with novel specificity and tested them on Xenopus oocytes expressing cloned nAChRs. We used rat and mouse α 6/3 subunit chimeras to model the α 6β2 and α 6β4 ligand binding domain because injection of non-chimeric α 6 with β 2 and β 3 fails to reliably produce functional expression (Dash et al., 2011; Dowell et al., 2003; Kuryatov et al., 2000; Papke et al., 2005) . However, comparison of data obtained from studies on heterologously expressed chimeric constructs of α 6 with studies on native α 6-containing nAChRs demonstrate that these chimeric constructs and native α 6-containing nAChRs share a similar pharmacological profile (Bordia et al., 2007; Capelli et al., 2011; Perez-Alvarez et al., 2012) . Using this strategy Construction of α 6/α3 subunit chimeras has been previously described and consists of an α 3 subunit where the first 237 amino acids of the ligand binding domain are replaced with the corresponding α 6 amino acids (McIntosh et al., 2004) . The rat α 6/α4 chimera was provided by R.
Papke (University of Florida, Gainesville, FL, USA)These chimeras were used because of poor expression of the non-chimeric forms of the α 6 construct. The human β 3-α6-β2-α4-β2 concatamer has been previously described (Kuryatov and Lindstrom, 2011) . Acetylcholine chloride (ACh) and bovine serum albumin were obtained from Sigma Aldrich (St. Louis, MO, USA). N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES) was purchased from
Research Organics (Cleveland, OH, USA).
Peptide Synthesis
Standard peptide chemistry was used to generate the α -Ctx peptides as previously described (Cartier et al., 1996) Detailed methods for conducting electrophysiological experiments of nAChRs heterologously expressed in Xenopus laevis oocytes have been previously described in detail (Hone et al., 2009 ).
Briefly, stage IV-V oocytes were injected with equal ratios of cRNA encoding cloned rat and mouse nAChR subunits α 3, The electrophysiology data were analyzed using GraphPad Prism software (La Jolla, CA, USA).
Concentration-response curves for inhibition of I ACh were generated by fitting the data to the Hill equation: % response = 100/{1 +([toxin]/IC 50 ) nH }. Data for observed on-rates (k obs ) were fit with a one-phase exponential equation and then analyzed by linear regression analysis to obtain an estimated value for k on . Observed off-rate kinetics were assessed by fitting the I ACh amplitudes with a one-phase exponential equation to obtain the plateau value of the I ACh ; observed values were then normalized to the plateau value and displayed as a percentage of the response to ACh.
Three-dimensional reconstructions of PeIA[S9H,V10A,E14N], MII, and PnIA were generated using PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC).
PeIA[S9H,V10A,E14N] was generated using the NMR structural coordinates of PeIA (Daly et al., 2011) as a template and the mutagenesis function of PyMOL. MII was also generated from NMR structural coordinates (Hill et al., 1998) and PnIA was generated from X-ray crystallography coordinates (Hu et al., 1996) . Structures were generated without consideration of alternative rotameric positions of the side chains.
This article has not been copyedited and formatted. The final version may differ from this version. Conus pergrandis and at the time of its discovery was noted to be the first peptide ligand that potently blocked α 9α10 but not α 7 nAChRs . However, PeIA also potently blocks several other nAChR subtypes including those that contain the α 6 subunit. PeIA shows a high degree of homology to other α -Ctxs that have 4 Cys residues that are connected by two disulfide bonds (Fig. 1A) . Structure function studies of α -Ctx MII, indicated that residues of the second disulfide loop interact with residues of the α 6 nAChR subunit (Azam et al., 2008; McIntosh et al., 2004; Pucci et al., 2011) . His residues in the 9 th and 12 th positions, and Asn in the 14 th position of MII are critical for conferring potency on α 6/α3β2β3 nAChRs (McIntosh et al., 2004) . For α -Ctx PnIA, Ala in the 10 th position is critical for subtype selectivity and potency for β 2-containing nAChRs (Hogg et al., 1999; Luo et al., 1999) . Therefore, we reasoned that mutations in the homologous positions of PeIA might not only be permissive for retaining activity, but might also confer beneficial changes in selectivity. We synthesized analogs that incorporated these non-conserved amino acids into the second disulfide loop of PeIA ( Fig 1A) .
These synthetic peptides were then evaluated for changes in potency and selectivity for the α 6/α3β2β3 subtype using two-electrode voltage-clamp electrophysiology of Xenopus oocytes expressing cloned nAChRs. Substitution of Ser for His in the 9 th position of PeIA increased the potency for inhibition of α 6/α3β2β3 nAChRs by ~11-fold; increased potency was also observed on α 3β2, α 6/α3β4, and α 3β4 nAChRs ( Fig. 2A) . In contrast, the S9H substitution resulted in an ~55-fold loss of potency on the α 9α10 subtype ( Fig. 2A) . Next, we evaluated an Ala substitution for Val in the 10 th position. Similar to the S9H analog, PeIA[V10A] showed increased activity on the α 6/α3β2β3 nAChR, but in contrast showed a ~2-fold loss of activity on α 6/α3β4 and α 3β4 nAChRs (Fig. 2B) . The net result of this substitution was an analog with ~126-fold selectivity for α 6/α3β2β3 vs. the α 6/α3β4 subtype. Finally, Asp was substituted for Glu14; although the activity was decreased for α 6/α3β2β3 by ~2-fold, there was an ~3-fold loss of activity for α 6/α3β4 and an ~15-fold loss for α 3β2 nAChRs (Fig. 2C) . Table 1 summarizes the changes in IC 50 values for inhibition of the four closely related α 3-and α 6-containing nAChR subtypes and compares the selectivity of each peptide for α 6/α3β2β3 relative to the α 6/α3β4 subtype.
We next examined the kinetics of block and unblock by PeIA and its singly substituted analogs. To obtain k obs , the oocytes were perfused with a concentration of peptide within 10-fold of the peptides' respective IC 50 values; 1-sec pulses of ACh were applied once every min until a steady state block of the I ACh was observed. To obtain k off , a concentration of peptide that blocked >95% of the I ACh (see Materials and Methods) was applied for 5 min in a static bath after which the peptide was washed out and I ACh was monitored for recovery. As shown in Fig. 3 , the kinetics of block and unblock by the parent peptide PeIA were similar for all four of the nAChR subtypes tested. Block and recovery from block was rapid and in most cases the t 1/2 s were < 30 sec. In contrast to the relatively rapid kinetics of PeIA, those of the S9H analog were markedly slower (Fig. 3) . Steady-state block by PeIA[S9H] of α 6/α3β2β3 nAChRs using a 1 nM concentration required ~11 min (t 1/2 = 2.2 min). Recovery from block was also slow and full recovery required ~30 min (t 1/2 = 6.2 min) of washout. The kinetics of the V10A analog were also slower than the native peptide but faster than PeIA[S9H] (Fig. 3 ). (Fig 2) produced improvements in either potency or selectivity for the α 6/α3β2β3
subtype. Therefore, we combined the S9H substitution with either the V10A or the E14N substitution to produce second generation analogs. As shown in Fig. 4 with an IC 50 value of 66.0 (51.5-84.7) nM and similar to the 65.4 (43.4-98.6) nM value obtained using chimeric α 6/α3β4 nAChRs (Fig. 5A) . We also tested this triply substituted PeIA analog on cloned mouse and cloned human α 6-containing nAChRs. The IC 50 values obtained for mouse α 6/α3β2β3 and α 6/α3β4 were also similar to those obtained using the rat counterparts (Fig. 5A) .
Likewise, the activity was also similar when tested on concatameric human α 6β2α4β2β3 (Fig.   5A ) and chimeric rat α 6/α4β2β3 nAChRs (Supplemental Figure 1) pM to 5 nM until steady-state block was achieved (Fig 6A) . The data were analyzed using a onephase exponential to obtain the k obs for each of the concentrations tested and the data plotted as a function of concentration. This analysis yielded a slope, or k on , of 0.228 ± 0.019 min -1 M -9 (Fig.   6B ). A k off value of 0.096 ± 0.001 min -1 was obtained by applying a high concentration of peptide to the oocyte in a 5 min static bath (Fig. 6C ). Since the dissociation constant is a ratio of k off to k on , an estimated K i value of 423 pM was obtained. Applying this same methodology to oocytes expressing α 6/α3β4 nAChRs over a concentration range of 10 nM to 500 nM yielded a k on of 0.699 ± 0.023 min -1 M -7 (Fig. 6D,E) and an observed k off value of 0.626 ± 0.02 min -1 . The estimated K i for α 6/α3β4 was ~90 nM, a value >200-fold higher than that determined for This article has not been copyedited and formatted. The final version may differ from this version. nAChRs were on average 94.0 ± 4% (Fig. 7A-C) .
Discussion α -Ctx PeIA was originally described as the first ligand that could discriminate between α 9α10 and α 7 nAChRs . It is noteworthy that while PeIA shares a similar activity profile with other α -Ctxs that target α 3β2 and α 6/α3β2β3 nAChRs, specifically MII (Cartier et al., 1996; McIntosh et al., 2004) and PnIA (Hogg et al., 1999; Hone et al., 2012; Luo et al., 1999) , it is only 42% similar to these peptides in non-cysteine amino acid homology (Fig.   1A ). Despite their sequence differences, molecular modeling and solution NMR studies predict that PeIA, MII, and PnIA all share a similar 3-dimensional backbone structure and occupy the acetylcholine binding pocket in approximately the same orientation (Daly et al., 2011; Rogers et al., 1999) . These differences and similarities suggest that specific residues of the peptides might be critical for binding to α 6β2-containing nAChRs. Thus, one aim of this study was to gain mechanistic insight into the binding of ligands with α 6β2-containing nAChRs.
To this end, we substituted specific amino acids of PeIA with those of MII and PnIA that are known to be critical for activity and evaluated the substituted analogs for changes in potency and selectivity for the α 6/α3β2β3 subtype.
This article has not been copyedited and formatted. The final version may differ from this version. Native PeIA shows a modest degree of separation (~13-fold) between the IC 50 values for α 6/α3β2β3 and the α 6/α3β4 subtypes. Thus, coupled with the known activity on other nAChR subtypes, PeIA is a non-selective antagonist of the five nAChR subtypes listed in Fig. 1B .
However, structure-function studies of α -Ctxs MII (McIntosh et al., 2004) , PnIA (Hogg et al., 1999; Luo et al., 1999) , and BuIA (Azam et al., 2010) suggested that PeIA would be a promising platform from which to develop α 6β2-selective ligands. These studies demonstrated that specific amino acids of MII confer high potency for the α 6/α3β2β3 subtype and that the 10 th position in
PnIA is critical for subtype selectivity and provided a rational strategy for engineering α 6/α3β2β3 subtype-selective ligands using PeIA as a template.
In this report, we describe the synthesis and characterization of a potent antagonist of α 6/α3β2β3 nAChRs achieved by substituting critical amino acids in the second loop of PeIA that increased potency and selectivity for α 6/α3β2β3 vs. α 6/α3β4 nAChRs. These amino acids included Ser9, Val10, and Glu14 and were substituted with His, Ala, and Asn, respectively.
When tested on Xenopus oocytes that expressed rat α 6/α3β2β3 and α 6/α3β4 nAChRs, the S9H substitution had the largest impact on potency and shifted the IC 50 value for inhibition of α 6/α3β2β3 nAChRs by ~11-fold while the V10A substitution had the largest effect on selectivity and conferred a ~10-fold increase in separation between the two subtypes ( Fig. 2A, B) over the native peptide. An additional ~5-fold increase in selectivity for α 6/α3β2β3 vs. α 6/α3β4 nAChRs over the native peptide was observed with the Glu for Asn substitution in the 14 th position (Fig.   2C ). The V10A and E14N substitutions were combined in pair-wise fashion with S9H with the expectation that double substitutions would retain the effects observed with each respective single substitution. (Fig 2A and 4A, B) . Finally, PeIA[S9H,V10A,E14N] was synthesized combining all three single substitutions to generate a ligand that was ~50-fold more potent than native PeIA for inhibition of α 6/α3β2β3 nAChRs ( Fig. 1B and 5A ) and produced an ~1800-fold improvement in selectivity for α 6/α3β2β3 vs. α 3β4 and an ~1700-fold improvement vs. α 7 nAChRs (IC 50 = 1.8 µM ) over native PeIA (5A,B). Most importantly, an ~280-fold improvement was observed for α 6/α3β2β3 vs. the α 6/α3β4 subtype (Fig. 5A ).
The kinetics of block and recovery from block were assessed on α 6/α3β2β3 nAChRs and compared to those obtained for the α 6/α3β4 subtype ( Fig. 6A-F) . These studies yielded a K i value for α 6/α3β2β3 (423 pM) that was >200-fold lower than that obtained for α 6/α3β4 (~90 nM) nAChRs (Fig. 6A-F) . Thus, at reasonable concentrations (5-10x the K i ) for inhibition of α 6/α3β2β3 nAChRs little inhibition of α 6/α3β4 nAChRs would be expected (Fig. 7) .
PeIA[S9H,V10A,E14N] was also tested on six other non-α6-containing nAChR subtypes and although inhibition of the two major CNS subtypes, α 4β2 and α 7, was observed, the IC 50 values were ~930-and ~1800-fold higher, respectively, than the IC 50 value for α 6/α3β2β3 nAChRs (Fig.   5A,B) . The peptide does, however, retain high potency for the α 3β2 subtype and cannot be used to discriminate between this subtype and α 6/α3β2β3 nAChRs.
An analog of α -Ctx MII, MII[E11A], also shows some selectivity (40-fold) for α 6/α3β2β3 vs. α 6/α3β4 nAChRs nAChRs (McIntosh et al., 2004) . PnIA also preferentially targets α 6/α3β2β3 nAChRs but with ~50-fold lower potency (Hone et al., 2012) than PeIA[S9H,V10A,E14N] and with significantly overlapping activity on the α 7 subtype (Luo et al., 1999) . We note that the sequence of PeIA[S9H,V10A,E14N] is 75% identical to that of and Whiteaker, 2011; Pivavarchyk et al., 2011; Pucci et al., 2011) . Significant heterogeneity of nAChR expression typifies many neuronal populations in the nervous system and such is the case in striatum where the predominant subtypes are α 6β2* and α 4β2* Perez et al., 2008) and in the ventral tegmental area where the predominant subtypes are α 6β2*, α 4β2*, α 7, and a currently uncharacterized β 4-containing nAChR (Jones and Wonnacott, 2004; Wooltorton et al., 2003; Wu et al., 2004; Yang et al., 2009) . In certain regions of the primate brain such as the cerebellum, substantial overlap of α 6, β 2, and β 4 subunit mRNAs have been found (Quik et al., 2000) . Furthermore, α 6β4* nAChRs have recently been identified in human adrenal chromaffin cells and characterized using analogs of MII (Perez-Alvarez et al., 2012) .
However, the analogs used in this study also potently block α 6/α3β2β3, but not α 3β2 nAChRs, and therefore the presence of α 6β2* nAChRs cannot be ruled out. The α 6β4* subtype has also been recently identified in a population of rat dorsal root ganglion neurons that also express β 2-containing nAChRs of the α 6β2* and/or the α 3β2* subtypes (Hone et al., 2012 McIntosh et al., 2004) . Thus an approach utilizing the selectivity profiles of both toxins may be useful for identifying the β 2-containing nAChRs in these neurons. The fact that PeIA[S9H,V10A,E14N] blocks rat, mouse, and human α 6β2-containing nAChRs with similar potencies while maintaining selectivity for α 6β2-vs α 6β4-containing nAChRs will allow the toxin to be used across species and thus should prove particularly useful for distinguishing α 6β2* from α 6β4* nAChRs in tissues where these receptors are potentially co-expressed. Finally, it is noteworthy that PeIA[S9H,V10A,E14N] is 1300-fold more potent at blocking α 3β2 than α 3β4
nAChRs. This exquisite selectivity for α 3β2 nAChRs may be useful for distinguishing between these two subtypes in neurons such as those found in intracardiac ganglia (Bibevski et al., 2000) This article has not been copyedited and formatted. The final version may differ from this version. and superior cervical ganglia (David et al., 2010; Mao et al., 2006 ) that predominantly express a mixed population of α 3-containing nAChRs.
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